![Ronald Cooper](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ronald Cooper
Amministratore Delegato presso
ENGENE THERAPEUTICS INC.
Patrimonio netto: 18 500 $ in data 31/05/2026
Profilo
Ronald Harold Wilfred Cooper is President, Chief Executive Officer & Director at enGene Therapeutics, Inc. since 2024.
Mr. Cooper is Chairman at C4 Therapeutics, Inc. since 2024.
Mr. Cooper was President, Chief Executive Officer & Director at Albireo AB. Mr. Cooper was President, Chief Executive Officer & Director at Albireo Pharma, Inc. from 2016 to 2023.
Mr. Cooper was Independent Director at Genocea Biosciences, Inc. from 2016 to 2021.
Mr. Cooper was Director at Albireo Ltd. from 2016 to 2021.
Mr. Cooper was Independent Director at Generation Bio Co. from 2021 to 2026.
Mr. Cooper was President-Europe at Bristol Myers Squibb Co. from 2010 to 2015.
Mr. Cooper completed undergraduate education at St. Francis Xavier University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 24/04/2026 | 10.000 ( 0,01% ) | 18 500 $ | 31/05/2026 | |
| 22/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Posizioni attive di Ronald Cooper
| Società | Posizione | Inizio |
|---|---|---|
| C4 THERAPEUTICS, INC. | Presidente | 07/06/2024 |
| ENGENE THERAPEUTICS INC. | Amministratore Delegato | 21/07/2024 |
Precedenti posizioni note di Ronald Cooper
| Società | Posizione | Fine |
|---|---|---|
| GENERATION BIO CO. | Direttore/Membro del Consiglio | 06/02/2026 |
| ALBIREO PHARMA, INC. | Amministratore Delegato | 02/03/2023 |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies that address medical needs in the gastrointestinal and liver disease area | Amministratore Delegato | 01/11/2016 |
| GENOCEA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 12/04/2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2015 |
Formazione di Ronald Cooper
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
61
Relazioni di 1° grado
9
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genocea Biosciences, Inc.
 Genocea Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that discovers and develops novel cancer immunotherapies | Health Technology |
St. Francis Xavier University
 St. Francis Xavier University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies that address medical needs in the gastrointestinal and liver disease area | Health Technology |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Develops bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders | Health Technology |
C4 Therapeutics, Inc.
 C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
Generation Bio Co.
 Generation Bio Co. Pharmaceuticals: MajorHealth Technology Develops and commercializes genetic medicines | Health Technology |
enGene Holdings, Inc.
 enGene Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops, manufactures and sells non-viral genetic medicines | Commercial Services |
